Project
A Multicenter Phase III Randomized study with second line chemotherapy plus or minus Bevacizumab in patients with Platinum sensitive Epithelial ovarian cancer recurrence after a Bevacizumab/chemotherapy first line. MITO-16b, MANGO-OV2b
Completed · 2020 until 2023
Weder Patrik, Harder Anja, Quinter Janine
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2020
End Date
2023
Financing
Industry
Labels
gynecological tumors